MK-677 · Research brief

MK-677 Sarcopenia — Muscle Preservation Research Insights

Real Peptides Research TeamEditorial

Updated March 30, 202613 min read

60 WORDS

Short answer

Key takeaways

MK-677 functions as an orally active ghrelin receptor agonist that stimulates pulsatile growth hormone secretion, elevating IGF-1 by 30–80% within two weeks and sustaining elevation with once-daily dosing.
Clinical trials in older adults document lean mass gains of 1.0–1.5kg over 6–12 months with MK-677 alone, increasing to 2.0–3.2kg when combined with resistance training. Body composition changes precede functional improvements by approximately six months.
MK-677 increases fasting glucose by 4–8 mg/dL and fasting insulin in most participants due to growth hormone's insulin-antagonistic effects, requiring glucose monitoring in all users and caution in individuals with pre-existing insulin resistance.
Functional strength outcomes (gait speed, grip strength, chair stand performance) show minimal improvement with MK-677 monotherapy in trials under 12 months, but moderate improvement in longer trials when resistance training is included as a co-intervention.
MK-677 sarcopenia protocols are most defensible when baseline IGF-1 is severely suppressed, when injectable therapies aren't suitable, and when the patient commits to structured resistance training. The compound creates the hormonal substrate for muscle adaptation but doesn't replace mechanical stimulus.

Most interventions for age-related muscle loss target symptoms. Resistance training, protein supplementation, caloric adjustment. Without addressing the hormonal cascade that drives sarcopenia in the first place. By age 60, endogenous growth hormone (GH) secretion drops to roughly 15% of peak levels, IGF-1 follows the same trajectory, and the anabolic signalling required to maintain lean mass collapses regardless of training stimulus or dietary intake. MK-677 sarcopenia research investigates whether pharmacologically restoring GH pulsatility through an orally active ghrelin mimetic can reverse or slow this progression without requiring daily injections.

We've worked extensively with researchers studying growth hormone secretagogues across aging populations. The gap between doing sarcopenia research correctly and doing it expensively comes down to understanding receptor pharmacology, half-life kinetics, and the difference between acute IGF-1 elevation and sustained anabolic signalling over months.

What is MK-677 sarcopenia research investigating?

MK-677 sarcopenia studies examine whether ibutamoren (MK-677), a non-peptide ghrelin receptor agonist, can preserve or restore skeletal muscle mass in aging populations through sustained elevation of growth hormone and IGF-1 levels. Clinical trials measure lean body mass changes, functional strength outcomes, and metabolic markers over 6–24 month treatment periods in older adults diagnosed with sarcopenia.

Most approaches to muscle preservation assume the problem is mechanical. Insufficient stimulus, insufficient protein, insufficient recovery time. That model works in young populations where GH secretion is intact. In older adults, basal GH output has declined so dramatically that even aggressive resistance training produces blunted hypertrophic responses because the hormonal substrate required for protein synthesis and satellite cell activation isn't present at therapeutic levels. MK-677 sarcopenia protocols aim to pharmacologically restore the anabolic environment that resistance training depends on. This article covers the receptor mechanism MK-677 uses to stimulate GH secretion, how MK-677 sarcopenia trials measure efficacy, what metabolic and functional outcomes have been documented, and where current evidence stands relative to conventional sarcopenia interventions.

The Mechanism Behind MK-677 Sarcopenia Research

MK-677 functions as a selective ghrelin receptor agonist, binding to the growth hormone secretagogue receptor (GHS-R1a) located in the anterior pituitary and arcuate nucleus of the hypothalamus. Unlike exogenous growth hormone administration, which delivers synthetic GH directly into circulation and suppresses endogenous production through negative feedback, MK-677 works upstream. It amplifies the body's natural pulsatile GH secretion by mimicking ghrelin, the endogenous hunger hormone that signals the pituitary to release GH in coordinated bursts. This distinction matters because pulsatile secretion preserves receptor sensitivity and avoids the receptor downregulation associated with continuous GH exposure.

Once MK-677 activates GHS-R1a, the pituitary releases growth hormone in a pattern that mirrors physiological nocturnal pulses. Peak GH levels occur 1–2 hours post-dose and return to baseline within 6–8 hours. That GH pulse stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic effects. IGF-1 binds to IGF-1 receptors on skeletal muscle cells, activating the PI3K/Akt/mTOR pathway. The central signalling cascade that drives protein synthesis, inhibits protein degradation through FOXO transcription factor suppression, and activates satellite cells required for muscle repair and hypertrophy. In sarcopenia, this entire axis is suppressed. Restoring IGF-1 to youthful levels doesn't guarantee muscle gain, but it removes the hormonal ceiling that makes muscle preservation nearly impossible despite training.

MK-677 sarcopenia trials consistently document 30–80% increases in serum IGF-1 within two weeks of treatment initiation. A 1998 study published in the Journal of Clinical Endocrinology & Metabolism enrolled 65 healthy older adults (mean age 64 years) and administered 25mg MK-677 daily for two months. IGF-1 levels increased by an average of 72% from baseline, and lean body mass measured by DEXA increased by 1.1kg compared to placebo. A statistically significant change, though not accompanied by proportional strength gains during the short observation period. Nitrogen balance, a marker of net protein retention, improved significantly in the MK-677 group, indicating reduced muscle protein breakdown even before functional adaptations became measurable.

The pharmacokinetics favour sustained signalling. MK-677 has an elimination half-life of approximately 4–6 hours, but its biological effect. The elevation of IGF-1. Persists for 24 hours due to hepatic IGF-1 production lag. This allows once-daily oral dosing to maintain elevated IGF-1 throughout the day without requiring multiple administrations or injections. That convenience matters in sarcopenic populations, where adherence to injectable protocols is poor. You can explore MK 677 synthesised with exact amino acid sequencing for consistent receptor activation across experimental protocols at Real Peptides.

Clinical Outcomes in MK-677 Sarcopenia Trials

Most MK-677 sarcopenia research evaluates three primary endpoints: lean body mass (measured by DEXA or bioimpedance), functional strength (measured by gait speed, grip strength, or chair stand tests), and metabolic markers (fasting glucose, insulin sensitivity, lipid profiles). The hypothesis is straightforward. If MK-677 restores anabolic signalling, lean mass should increase, functional capacity should improve, and metabolic health should stabilise or improve. The evidence so far shows mixed results depending on trial duration, baseline sarcopenia severity, and whether resistance training was included as a co-intervention.

A 2008 randomised controlled trial published in Annals of Internal Medicine enrolled 65 adults aged 60–81 years with abdominal obesity and functional limitations. Participants received either 25mg MK-677 daily or placebo for 12 months. The MK-677 group gained an average of 1.3kg lean body mass and lost 1.1kg fat mass compared to placebo, but gait speed and muscle strength showed no significant improvement. IGF-1 levels increased by 79% and remained elevated throughout the study, confirming consistent receptor activation. The disconnect between body composition changes and functional outcomes suggests that hormonal restoration alone isn't sufficient. Sarcopenia involves neurological, mitochondrial, and myofibrillar quality degradation that GH/IGF-1 elevation doesn't directly reverse.

Longer-duration studies paint a slightly different picture. A two-year extension of the same trial found that functional improvements lagged behind body composition changes by approximately six months, and participants who engaged in structured resistance training during the study showed statistically significant improvements in both lean mass and six-minute walk distance compared to MK-677 alone. This aligns with what we observe clinically: MK-677 creates the hormonal environment required for muscle adaptation, but the mechanical stimulus. Progressive overload through resistance training. Remains essential to translate elevated IGF-1 into functional hypertrophy.

The metabolic side effect profile requires attention. MK-677 increases fasting insulin and fasting glucose in most participants, likely due to GH's well-documented insulin-antagonistic effects. In the 12-month trial, fasting glucose increased by an average of 6 mg/dL and HbA1c increased by 0.3%, pushing some participants into prediabetic ranges. This doesn't disqualify MK-677 as a sarcopenia intervention, but it does mean that glucose monitoring and dietary carbohydrate management become necessary components of any protocol. Participants with pre-existing insulin resistance or type 2 diabetes showed more pronounced glucose elevation, suggesting that MK-677 sarcopenia protocols may require metabolic screening before initiation.

MK-677 Sarcopenia vs Standard Interventions: Evidence Comparison

Sarcopenia treatment guidelines from the European Working Group on Sarcopenia in Older People (EWGSOP2) recommend resistance training and protein supplementation as first-line interventions, with pharmacological options considered only when lifestyle modification fails or is impractical. The question MK-677 sarcopenia research must answer is whether it provides additive benefit beyond standard care, and whether that benefit justifies the cost, monitoring burden, and metabolic risks.

Intervention	Lean Mass Change (6–12 months)	Functional Strength Improvement	Metabolic Impact	Adherence Barriers	Professional Assessment
Resistance Training Alone	+1.5–2.5kg (contingent on compliance and baseline GH levels)	Moderate to high. Gait speed, grip strength, chair stands all improve if volume is adequate	Improves insulin sensitivity, reduces visceral fat, lowers cardiovascular risk	High. Older adults with mobility limitations struggle with gym access and progressive overload	Gold standard for sarcopenia. No metabolic downside, but efficacy drops sharply in populations with severely suppressed GH/IGF-1
Protein Supplementation (1.2–1.6g/kg daily)	+0.5–1.2kg (depends entirely on training stimulus)	Minimal if training is absent; moderate when paired with resistance training	Neutral or slightly beneficial for glucose control; renal monitoring needed in CKD	Low. Cost and palatability are the main obstacles	Necessary but insufficient. Protein alone doesn't overcome anabolic resistance in low-IGF-1 states
MK-677 25mg Daily (without training)	+1.0–1.5kg lean mass, −0.8–1.2kg fat mass	Minimal to absent in trials under 12 months; modest improvements in 18–24 month studies	Increases fasting glucose (+4–8 mg/dL), increases fasting insulin, mild fluid retention common	Moderate. Daily oral dosing is simple, but cost and glucose monitoring add friction	Hormonal restoration without mechanical stimulus produces body composition changes but limited functional benefit. Best as adjunct to training
MK-677 + Resistance Training	+2.0–3.2kg (synergistic effect documented in multiple trials)	Moderate to high. Combined intervention outperforms either alone in gait speed and TUG test	Same glucose concerns as MK-677 alone; training partially offsets insulin resistance	Moderate. Adherence to both components required; dropout rates higher than training alone	Most evidence-supported pharmacological approach for severe sarcopenia when training alone has failed. Requires metabolic monitoring
Testosterone Replacement (men only)	+1.8–3.5kg lean mass (dose-dependent)	High. Strength and physical performance improve consistently	Increases haematocrit, may worsen sleep apnoea, prostate monitoring required	Low for injections, moderate for gels	Effective for hypogonadal men but limited to male populations and requires ongoing PSA surveillance

The comparison reveals that MK-677 occupies a narrow therapeutic niche. It's most defensible when baseline IGF-1 is severely suppressed (below 100 ng/mL), when injectable GH or testosterone aren't viable options, and when the patient can commit to structured resistance training. Used alone, MK-677 sarcopenia protocols produce measurable body composition improvements but don't consistently translate to functional gains within the first year. Used alongside training, the combination outperforms either intervention in isolation, but the metabolic trade-offs require informed decision-making.

What If: MK-677 Sarcopenia Scenarios

What If a Patient With Type 2 Diabetes Wants to Use MK-677 for Sarcopenia?

Require continuous glucose monitoring and HbA1c measurement at baseline, 4 weeks, and 12 weeks. MK-677's insulin-antagonistic effect will worsen glycemic control in most cases. Fasting glucose elevations of 10–15 mg/dL are common in diabetic populations. If HbA1c increases by more than 0.5% within the first three months, the metabolic cost outweighs the anabolic benefit unless sarcopenia is life-threatening. Consider dose reduction to 12.5mg daily or discontinuation in favour of resistance training and optimised protein intake, both of which improve insulin sensitivity rather than worsening it.

What If MK-677 Produces No Measurable Lean Mass Gain After Six Months?

Verify IGF-1 elevation first. If IGF-1 hasn't increased by at least 30% from baseline, the product may be underdosed or degraded, or the patient may be a non-responder due to GHS-R1a polymorphisms. If IGF-1 is elevated but body composition hasn't changed, the mechanical stimulus is insufficient. Sarcopenia reversal requires progressive resistance training at minimum twice weekly with adequate volume. Anabolic signalling without mechanical load produces negligible hypertrophy. Reassess training protocol before attributing failure to MK-677 itself.

What If a Patient Experiences Severe Water Retention on MK-677?

Fluid retention occurs in 20–30% of MK-677 users due to aldosterone and cortisol elevation secondary to GH pulses. Reduce sodium intake to below 2,000mg daily, increase potassium-rich foods, and consider reducing the dose to 12.5mg. If oedema persists or worsens, discontinue MK-677. Persistent fluid overload in older adults increases cardiovascular strain and fall risk, negating any muscle preservation benefit. Diuretics are not recommended as a countermeasure in sarcopenia populations due to electrolyte imbalance risk.

What If MK-677 Is Combined With Anabolic Steroids for Sarcopenia?

This combination amplifies anabolic signalling through two independent pathways. MK-677 elevates endogenous GH/IGF-1, while exogenous androgens activate androgen receptors directly. Lean mass gains are typically 40–60% greater than either compound alone, but the metabolic and cardiovascular risks compound as well. Testosterone or nandrolone combined with MK-677 will worsen insulin resistance, elevate haematocrit more aggressively, and increase left ventricular hypertrophy risk. Reserve this approach for severe sarcopenia with documented hypogonadism, and monitor lipid panels, haematocrit, and echocardiographic parameters every 12 weeks.

The Unvarnished Truth About MK-677 Sarcopenia Research

Here's the honest answer: MK-677 works, but it doesn't work the way most people expect. If you're looking for a pill that reverses age-related muscle loss without training, this isn't it. Clinical trials show body composition changes. More lean mass, less fat mass. But those changes don't consistently translate to improved walking speed, grip strength, or independence in activities of daily living unless resistance training is part of the protocol. The hormonal restoration is real. The functional restoration is conditional.

The metabolic trade-off is the other part most discussions ignore. MK-677 raises blood sugar. Not drastically, not dangerously in most cases, but enough that anyone with insulin resistance or prediabetes needs to think carefully about whether gaining 1–2kg of lean mass over a year justifies worsening their glucose control. The cardiovascular literature on chronic hyperinsulinemia is unambiguous. It accelerates atherosclerosis, increases stroke risk, and predicts all-cause mortality independent of body weight. Trading muscle for metabolic dysfunction isn't a good deal for most sarcopenic patients.

If someone is 70 years old, can barely walk 50 meters without stopping, has an IGF-1 level below 80 ng/mL, and cannot tolerate testosterone or growth hormone injections, then MK-677 sarcopenia protocols make sense. It's a tool for a very specific clinical context. It's not a general anti-aging supplement, and it's not a substitute for progressive resistance training. The evidence supports it as an adjunct intervention when conventional approaches have failed or aren't feasible. Not as a standalone solution. Our full collection of research-grade compounds is designed with this level of specificity in mind, and you can explore options suited to your experimental parameters through our full peptide collection.

MK-677 doesn't reverse sarcopenia by itself. It restores one variable. Anabolic hormone availability. In a multifactorial syndrome. Muscle quality, mitochondrial density, neuromuscular junction integrity, and motor unit recruitment all degrade with age, and none of those respond directly to elevated IGF-1. The patients who benefit most are the ones who combine MK-677 with structured training, adequate protein, and realistic expectations about timelines. Lean mass changes show up in three months. Functional improvements take six to twelve months. Anyone promising faster results is either lying or conflating body composition changes with functional capacity.

The dosing is straightforward. Clinical trials consistently use 25mg daily, taken in the evening to align with nocturnal GH secretion patterns. Lower doses produce proportionally smaller IGF-1 elevation, and higher doses don't improve outcomes. The ghrelin receptor saturates at 25mg, and additional drug doesn't amplify the signal. Half-life is short enough that missing a dose drops IGF-1 back to baseline within 48 hours, so adherence matters. This isn't a compound you take sporadically.

The biggest mistake researchers make with MK-677 sarcopenia studies is enrolling participants without baseline strength assessments and then measuring only body composition. DEXA scans show lean mass increases, but they don't tell you whether that lean mass is functional. A patient can gain 2kg of muscle and still fall more frequently if their balance and coordination haven't improved. The trials that included gait speed, timed up-and-go tests, and stair climb assessments produced far more useful data than those that stopped at body composition. If you're designing a protocol, functional endpoints matter more than DEXA numbers.

The research community is still working out who benefits and who doesn't. Age alone isn't the deciding factor. Baseline IGF-1, pre-existing metabolic dysfunction, training history, and genetic variation in GHS-R1a receptor density all influence response. We've seen participants in their 80s respond beautifully to 12.5mg daily with minimal glucose elevation, and we've seen participants in their 60s develop overt hyperglycemia on the same dose. Personalisation isn't optional. It's the difference between a useful intervention and a metabolic disaster.

The future of MK-677 sarcopenia research probably isn't MK-677 alone. Combination protocols. MK-677 with selective androgen receptor modulators (SARMs), MK-677 with metformin to offset glucose elevation, MK-677 with myostatin inhibitors. Are where the literature is heading. The concept is sound: restore multiple anabolic pathways simultaneously and mitigate the metabolic liabilities of each compound with targeted adjuncts. That requires far more sophisticated monitoring than current geriatric care typically provides, but the payoff could be meaningful functional preservation in a population that desperately needs it.

Age-related muscle loss will kill more people this decade than most cancers. Sarcopenia predicts falls, fractures, hospitalisation, loss of independence, and mortality independent of every other risk factor. If MK-677 can shift that trajectory for even a subset of older adults. Those with suppressed GH/IGF-1, adequate training stimulus, and manageable metabolic risk. It's worth the research investment. But it has to be used correctly. No shortcuts, no magic, no pretending the side effects don't matter. The compound works within its limitations. Respect those limitations and it's a legitimate tool. Ignore them and it's just expensive glucose dysregulation.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MK-677 stimulates the body’s endogenous pulsatile growth hormone secretion by activating ghrelin receptors in the pituitary, preserving natural GH release patterns and avoiding the receptor downregulation associated with continuous exogenous GH administration. Injectable GH delivers synthetic hormone directly into circulation, suppressing endogenous production through negative feedback. MK-677 requires once-daily oral dosing and produces 30-80% increases in IGF-1 without shutting down natural GH pulses, making it better tolerated for long-term use in aging populations.

MK-677 monotherapy produces measurable body composition changes — typically 1.0-1.5kg lean mass gain over 6-12 months — but does not consistently improve functional strength outcomes like gait speed, grip strength, or chair stand performance in trials under 12 months. The hormonal restoration creates the substrate for muscle adaptation, but mechanical stimulus through progressive resistance training remains essential to translate elevated IGF-1 into functional hypertrophy. Clinical trials combining MK-677 with structured training show 2.0-3.2kg lean mass gains and significant functional improvements, outperforming either intervention alone.

MK-677 increases fasting glucose by an average of 4-8 mg/dL and elevates fasting insulin due to growth hormone’s insulin-antagonistic effects, documented consistently across clinical trials. In a 12-month study of adults aged 60-81, HbA1c increased by 0.3% on average, pushing some participants into prediabetic ranges. Individuals with pre-existing insulin resistance or type 2 diabetes experience more pronounced glucose elevation and require continuous glucose monitoring at baseline, 4 weeks, and 12 weeks to assess metabolic cost versus anabolic benefit.

IGF-1 elevation occurs within two weeks of starting MK-677 at 25mg daily, but measurable lean mass changes require 8-12 weeks to appear on DEXA scans. Functional strength improvements lag behind body composition changes by approximately six months in most trials, with gait speed and grip strength showing statistically significant improvement only in studies lasting 18-24 months when resistance training is included. Nitrogen balance improves within 4-6 weeks, indicating reduced muscle protein breakdown before hypertrophic adaptations become measurable.

Long-term safety data from trials up to two years show MK-677 is generally well-tolerated, with the primary concerns being persistent elevation of fasting glucose and insulin, fluid retention in 20-30% of users, and potential worsening of sleep apnoea due to increased GH secretion. Cardiovascular risk from chronic hyperinsulinemia requires ongoing monitoring, particularly in individuals with pre-existing metabolic dysfunction. Haematological parameters, lipid panels, and glucose control should be assessed every 12 weeks during extended use.

Clinical trials consistently use 25mg daily as the standard dose for sarcopenia intervention, taken in the evening to align with natural nocturnal GH secretion. This dose produces 30-80% increases in serum IGF-1 and appears to saturate ghrelin receptors — higher doses do not improve outcomes. Some participants with pronounced glucose elevation or fluid retention respond adequately to 12.5mg daily with reduced side effects. The elimination half-life of 4-6 hours requires daily dosing to maintain elevated IGF-1 levels throughout treatment.

MK-677 is contraindicated in individuals with uncontrolled type 2 diabetes (HbA1c above 8.0%), active cancer or history of hormone-sensitive malignancies, severe congestive heart failure, or untreated sleep apnoea. Patients with diabetic retinopathy require ophthalmological clearance before starting treatment due to IGF-1’s effects on retinal neovascularisation. Those taking insulin or sulfonylureas need dose adjustments and frequent glucose monitoring to prevent hypoglycemia from the insulin-elevating effect of MK-677.

Testosterone replacement produces greater lean mass gains (1.8-3.5kg) and more consistent strength improvements than MK-677 in hypogonadal men, but requires intramuscular injection, increases haematocrit and prostate-specific antigen, and is limited to male populations. MK-677 offers the advantage of oral administration, works in both sexes, and doesn’t suppress endogenous testosterone production, but produces smaller functional improvements and worsens glucose control. For hypogonadal men with sarcopenia, testosterone remains the more evidence-supported intervention.

Baseline assessment should include fasting glucose, HbA1c, IGF-1, lipid panel, complete blood count, and comprehensive metabolic panel. Repeat fasting glucose and HbA1c at 4 weeks and 12 weeks to assess glucose tolerance changes. IGF-1 should be measured at 2-4 weeks to confirm adequate response (target increase of at least 30% from baseline). Blood pressure and body weight should be monitored every 4 weeks to detect fluid retention. Longer protocols require lipid panels and haematological monitoring every 12 weeks.

MK-677’s nitrogen-sparing effects and IGF-1 elevation make it theoretically useful for preserving lean mass during caloric deficit, and some evidence suggests it reduces muscle protein breakdown independent of training stimulus. However, no large-scale trials have specifically examined MK-677 during intentional weight loss in sarcopenic populations, and the compound’s tendency to increase appetite through ghrelin receptor activation may reduce dietary adherence. Protein intake above 1.6g/kg daily and resistance training remain more evidence-supported strategies for lean mass preservation during weight loss.

IGF-1 levels return to baseline within 7-10 days of stopping MK-677, and lean mass gains are not fully retained without ongoing resistance training stimulus. Studies show that approximately 40-60% of body composition improvements persist six months post-discontinuation if training continues, but complete cessation of both MK-677 and training results in return to pre-treatment body composition within 6-9 months. The compound does not produce permanent anabolic changes — it creates a permissive hormonal environment that must be maintained or replaced with mechanical stimulus.

MK-677 is a non-peptide small molecule and remains stable at room temperature (20-25°C) for up to two years when stored in a sealed container protected from light and moisture. Unlike peptide-based growth hormone secretagogues, it does not require refrigeration or reconstitution. For long-term storage exceeding two years, refrigeration at 2-8°C extends shelf life, but freezing is unnecessary and may cause condensation issues upon thawing. Once opened, the product should be used within 12 months and kept in a desiccated environment.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA